Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A randomized controlled prospective clinical trial assessing the efficacy and safety of progressive esophageal dilation compared to conservative esophageal dilation in patients with severe benign esophageal strictures.
A randomized controlled prospective clinical trial assessing the efficacy and safety of progressive esophageal dilation (up to 6mm) compared to esophageal dilation according to the rule-of-3 in patients with severe benign esophageal strictures. Patients will be followed up for 6 months. When recurrent dysphagia occurs within 6 months the patients will be dilated according to the previously allocated strategy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Progressive | Experimental | Patients will be dilated > 3mm and can be dilated up to 6mm in diameter |
|
| Conservative (rule-of-3) | Active Comparator | Patients will be dilated according to the rule-of-3 (i.e. dilation of no more than 3mm in diameter) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Savary bougie dilation | Device | Patients will be dilated with the use of the Savary bougienage device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total number of dilation procedures within 6 months of follow-up | Total number of dilation procedures within 6 months of follow-up | 6 months |
| Total number of dilation procedures during first dilation session to 16-18mm | Total number of dilation procedures during first dilation session to 16-18mm | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Dysphagia free patients | Number of patients remaining dysphagia free within 6 months after dilation to 16-18mm | 6 months |
| Timeframe first dilation session | Time from first dilation session to dilation of 16-18mm |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Endoscopic exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bram Vermeulen, Drs. | Contact | 0611079557 | +31 | bram.vermeulen@radboudumc.nl |
| Peter Siersema, Dr. | Contact | 06 547 84 967 | +31 | peter.siersema@radboudumc.nl |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Radboudumc | Recruiting | Nijmegen | Gelderland | 6500HB | Netherlands |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
randomized controlled patient groups
Not provided
Not provided
Participant will be blinded for dilation strategy.
| 1 month |
| Dysphagia free time period | Time to dilation of recurrent stricture after initial dilation to 16-18mm | 6 months |
| Incidence of treatment-related mortality (serious) adverse events (safety) | Incidence of treatment-related mortality (serious) adverse events (safety) | 7 months |
| Quality of Life | SF-36, disease specific questionnaire | 6 months |
| Medical costs | Direct medicals costs: procedures, secondary interventions | 7 months |